Joseph P. Gardner

2.6k total citations · 1 hit paper
8 papers, 2.1k citations indexed

About

Joseph P. Gardner is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Joseph P. Gardner has authored 8 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Immunology, 3 papers in Oncology and 2 papers in Molecular Biology. Recurrent topics in Joseph P. Gardner's work include T-cell and B-cell Immunology (3 papers), Peptidase Inhibition and Analysis (2 papers) and Immunotherapy and Immune Responses (2 papers). Joseph P. Gardner is often cited by papers focused on T-cell and B-cell Immunology (3 papers), Peptidase Inhibition and Analysis (2 papers) and Immunotherapy and Immune Responses (2 papers). Joseph P. Gardner collaborates with scholars based in United States and Denmark. Joseph P. Gardner's co-authors include Patricia A. Connelly, Paul S. Changelian, Brian A. Pollok, Elora J. Weringer, Robert L. Dow, Jeffrey H. Hanke, William H. Brissette, Rodney Morgan, Mark J. Neveu and Ellen Chuang and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Immunity.

In The Last Decade

Joseph P. Gardner

8 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor

1996 1.8k citations Jeffrey H. Hanke, Joseph P. Gardner et al. Journal of Biological Chemistry profile →

Peers

Countries citing papers authored by Joseph P. Gardner

Since Specialization

Citations

This map shows the geographic impact of Joseph P. Gardner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph P. Gardner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph P. Gardner more than expected).

Fields of papers citing papers by Joseph P. Gardner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph P. Gardner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph P. Gardner. The network helps show where Joseph P. Gardner may publish in the future.

Co-authorship network of co-authors of Joseph P. Gardner

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph P. Gardner. A scholar is included among the top collaborators of Joseph P. Gardner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph P. Gardner. Joseph P. Gardner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

#	Work	Indexed citations
1	Regulation of apoAI processing by procollagen C-proteinase enhancer-2 and bone morphogenetic protein-1 2009 ·Journal of Lipid Research ·Jian Zhu, Joseph P. Gardner, Clive R. Pullinger, John P. Kane, John F. Thompson, Omar L. Francone	24
2	In vitro characterization and pre-clinical pharmacokinetics of CP-870,893, a human anti-CD40 agonist antibody 2006 ·Journal of Clinical Oncology ·Vahe Bedian, Carol Donovan, Joseph P. Gardner, Edward J. Natoli, Timothy Paradis, (unknown), (unknown), Richard M. Shepard, (unknown), Ronald P. Gladue	8
3	Preclinical in vitro characterization of anti-CTLA4 therapeutic antibody CP-675,206. 2004 ·Cancer Research ·Douglas C. Hanson, Paul C. Canniff, Michael J. Primiano, Carol Donovan, Joseph P. Gardner, Edward J. Natoli, Rodney Morgan, Robert J. Mather, David H. Singleton, (unknown), Mark J. Neveu, Glenn C. Andrews, (unknown), Eileen A. Elliott, Vahe Bedian	30
4	The CD28 and CTLA-4 Receptors Associate with the Serine/Threonine Phosphatase PP2A 2000 ·Immunity ·Ellen Chuang, Timothy S. Fisher, Rodney Morgan, Michael Robbins, James M. Duerr, Matthew G. Vander Heiden, Joseph P. Gardner, John Hambor, Mark J. Neveu, Craig B. Thompson	248
5	Phenotypic characterization and analysis of allogeneic T cell responses in ZAP-70 dominant negative transgenic mice 1997 ·Clinical & Experimental Immunology ·Ronald P. Gladue, Melanie Allen, Ann Cunningham, Joseph P. Gardner, (unknown), Patricia A. Connelly, Andréy S. Shaw, John McNeish	5
6	Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor breakdown → 1996 ·Journal of Biological Chemistry ·Jeffrey H. Hanke, Joseph P. Gardner, Robert L. Dow, Paul S. Changelian, William H. Brissette, Elora J. Weringer, Brian A. Pollok, Patricia A. Connelly	1773
7	Potent Activation of Phosphatidylinositol 3'-Kinase by Simple Phosphotyrosine Peptides Derived from Insulin Receptor Substrate 1 Containing Two YMXM Motifs for binding SH2 Domains 1994 ·Biochemistry ·John J. Herbst, Glenn C. Andrews, Leonard G. Contillo, (unknown), Joseph P. Gardner, Gustav E. Lienhard, E. Michael Gibbs	41
8	“Spot transfer”, elution and comigration with known proteins allows accurate transferral of protein identifications between distinct two‐dimensional electrophoretic systems 1994 ·Electrophoresis ·David P. Dean, (unknown), (unknown), Joseph P. Gardner, Patricia A. Connelly, Julio E. Celis	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact